Suzuken Co (9987) AI Stock Analysis

• Market Cap: $332.47B
• Dividend Yield: 1.7%
• Average Volume (3M): 163.97K
• Price to Earnings (P/E): 13.3
• Beta (1Y): 0.43
• Revenue Growth: 0.65%
• EPS Growth: 16.05%
• Country: JP
• Employees: 13,086
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 52.63
• Shares Outstanding: 72,167,206
• 10 Day Avg. Volume: 143,650
• 30 Day Avg. Volume: 163,966
• PEG Ratio: 0.40
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 0.16
• P/FCF Ratio: -4.48
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 0.11
• Enterprise Value/Gross Profit: 1.33
• Enterprise Value/Ebitda: 5.18
• 1Y Price Target: $6,285.59
• Price Target Upside: 7.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 69 Neutral
• Price Target: ¥6,387.00 ▲(9.05% Upside)

Suzuken Co's overall stock score reflects a strong balance sheet and moderate valuation, but is tempered by significant revenue decline and cash flow challenges. Technical indicators suggest a stable market position, but the lack of earnings call data and corporate events limits further insights.

Suzuken Co Business Overview & Revenue Model

Company Description

Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.

How the Company Makes Money

Suzuken Co. generates revenue primarily through its distribution services, where it acts as an intermediary between pharmaceutical manufacturers and healthcare providers, including hospitals and pharmacies. The company's revenue model is based on the markup it applies to the products it distributes, which includes a wide range of prescription medications, over-the-counter drugs, and medical supplies. Key revenue streams also include logistics services and IT solutions provided to clients, enhancing supply chain efficiency and data management in healthcare settings. Additionally, Suzuken has established partnerships with various pharmaceutical companies, enabling it to secure a diverse product portfolio and maintain competitive pricing, further contributing to its earnings.

Suzuken Co Financial Statement Overview

Summary

Suzuken Co's financial performance is marked by a strong balance sheet with low leverage and effective equity utilization. However, the sharp decline in revenue growth and cash flow issues are significant concerns that need addressing to ensure liquidity and operational sustainability.

Income Statement

Suzuken Co's income statement shows a stable gross profit margin of around 8% over the years, indicating consistent cost management. The net profit margin has improved slightly, reaching 1.44% in the latest year, reflecting better profitability. However, the revenue growth rate has turned negative at -45.2%, which is a significant concern. EBIT and EBITDA margins have shown slight improvements, suggesting operational efficiencies.

Balance Sheet

The balance sheet of Suzuken Co is strong, with a very low debt-to-equity ratio of 0.0044, indicating minimal leverage and financial risk. The return on equity has improved to 8.47%, showing effective use of equity to generate profits. The equity ratio is healthy, suggesting a stable financial structure with a good proportion of assets financed by equity.

Cash Flow

Cash flow analysis reveals challenges, with negative operating and free cash flows in the latest period, indicating liquidity issues. The free cash flow to net income ratio is positive, suggesting that despite negative cash flows, the company is generating sufficient net income. However, the operating cash flow to net income ratio is negative, highlighting potential cash flow management issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.41T	2.40T	2.39T	2.31T	2.23T	2.13T
Gross Profit	192.18B	192.23B	185.25B	179.69B	167.33B	157.84B
EBITDA	49.42B	62.38B	51.40B	39.48B	32.55B	22.92B
Net Income	33.32B	34.50B	29.02B	20.34B	14.39B	7.89B
Balance Sheet
Total Assets	1.15T	1.11T	1.23T	1.15T	1.14T	1.11T
Cash, Cash Equivalents and Short-Term Investments	142.20B	141.58B	242.11B	192.70B	201.46B	212.12B
Total Debt	23.85B	1.80B	1.80B	1.80B	2.12B	2.28B
Total Liabilities	744.12B	706.41B	812.26B	734.57B	723.66B	696.51B
Stockholders Equity	402.16B	407.29B	416.31B	411.21B	417.69B	417.05B
Cash Flow
Free Cash Flow	0.00	-83.73B	71.58B	19.53B	-4.77B	7.74B
Operating Cash Flow	0.00	-65.08B	87.22B	37.27B	9.52B	15.60B
Investing Cash Flow	0.00	20.38B	10.35B	-46.36B	1.44B	-14.59B
Financing Cash Flow	0.00	-35.48B	-31.72B	-26.22B	-11.60B	-7.39B

Suzuken Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5857.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9987, the sentiment is Positive. The current price of 5857 is above the 20-day moving average (MA) of 5832.79, above the 50-day MA of 5854.36, and above the 200-day MA of 5204.46, indicating a bullish trend. The MACD of 6.66 indicates Positive momentum. The RSI at 50.57 is Neutral, neither overbought nor oversold. The STOCH value of 44.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9987.

Suzuken Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2784	72 Outperform	$410.66B	14.27	5.93%	3.07%	4.35%	-5.14%
3151	71 Outperform	¥58.22B	9.01	―	4.47%	2.22%	21.19%
9987	69 Neutral	$332.47B	13.30	8.26%	1.70%	0.65%	16.05%
8129	68 Neutral	¥330.98B	14.98	―	1.68%	1.51%	3.14%
7459	66 Neutral	$467.38B	12.89	6.81%	2.56%	3.51%	5.22%
3549	63 Neutral	¥397.26B	22.04	―	0.37%	15.81%	27.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Suzuken Co Corporate Events

Suzuken Co. Revises Financial Forecast Upward Amid Strong Sales

Suzuken Co., Ltd. has revised its full-year consolidated financial results forecast for the fiscal year ended March 31, 2025. The revision reflects an increase in net sales driven by new drugs and COVID-19-related products, leading to higher operating and net income than previously anticipated. This adjustment indicates a positive impact on Suzuken’s financial performance and suggests strengthened market positioning due to effective cost management and strategic product offerings.